All Stories

  1. Assisted peritoneal dialysis in France threatened by restrictive interpretation of legislation by CPAM?

    Article • Bulletin de la Dialyse à Domicile, December 2025, Registre de Dialyse Peritoneale de Langue Francaise (RDPLF)

    MD-PhD GUY ROSTOKER

  2. Evidence of pancreatic iron deposits and their association with mortality in dialysis-associated iatrogenic hemosiderosis

    Article • Clinical Kidney Journal, October 2025, Oxford University Press (OUP)

    MD-PhD GUY ROSTOKER

  3. #2682 Real costs of daily home hemodialysis compared to in-center hemodialysis in France

    Article • Nephrology Dialysis Transplantation, October 2025, Oxford University Press (OUP)

    MD-PhD GUY ROSTOKER

  4. #2750 Daily home hemodialysis is associated with a lower mortality rate compared with in-center hemodialysis in French patients

    Article • Nephrology Dialysis Transplantation, October 2025, Oxford University Press (OUP)

    MD-PhD GUY ROSTOKER

  5. Serological Correlate of Protection Established by Neutralizing Antibodies Differs Among Dialysis Patients with SARS-CoV-2 Variants of Concern

    Article • Vaccines, May 2025, MDPI AG

    MD-PhD GUY ROSTOKER

  6. Cost-effectiveness of daily home haemodialysis versus in-centre haemodialysis: A propensity score matching analysis based on real-world data from the French healthcare system

    Article • European Journal of Internal Medicine, May 2025, Elsevier

    MD-PhD GUY ROSTOKER

  7. mRNA vaccine against SARS-CoV-2 response is comparable between patients on dialysis and healthy controls after adjustment for age, gender and history of COVID-19 infection

    Article • Journal of Nephrology, December 2024, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  8. Impact of iron and erythropoiesis-stimulating agent dose on mortality of hemodialysis patients with cancer

    Article • Journal of Nephrology, December 2024, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  9. Clustering Analysis Identified Distinct Clinical Phenotypes among Hemodialysis Patients in Their Immunological Response to the BNT162b2 mRNA Vaccine against SARS-CoV-2

    Article • Vaccines, October 2024, MDPI AG

    MD-PhD GUY ROSTOKER

  10. Dialysis nurse demand in Europe: an estimated prediction based on modelling

    Article • Clinical Kidney Journal, June 2024, Oxford University Press (OUP)

    MD-PhD GUY ROSTOKER

  11. Relationship between bone marrow iron load and liver iron concentration in dialysis-associated haemosiderosis

    Article • EBioMedicine, January 2024, Elsevier

    MD-PhD GUY ROSTOKER

  12. Interest of HIF stabilizers in home dialysis

    Article • Bulletin de la Dialyse à Domicile, April 2023, Registre de Dialyse Peritoneale de Langue Francaise (RDPLF)

    MD-PhD GUY ROSTOKER

  13. Cost of Home Dialysis in France

    Article • Bulletin de la Dialyse à Domicile, September 2022, Registre de Dialyse Peritoneale de Langue Francaise (RDPLF)

    MD-PhD GUY ROSTOKER

  14. Stage V Chronic Kidney Disease: A plea for Home Dialysis

    Article • Bulletin de la Dialyse à Domicile, September 2022, Registre de Dialyse Peritoneale de Langue Francaise (RDPLF)

    MD-PhD GUY ROSTOKER

  15. Financial Barriers to the Optimal Use of Peritoneal Dialysis in France and Europe, as in the United States

    Article • Journal of the American Society of Nephrology, August 2022, American Society of Nephrology

    MD-PhD GUY ROSTOKER

  16. Differential Pharmacokinetics of Liver Tropism for Iron Sucrose, Ferric Carboxymaltose, and Iron Isomaltoside: A Clue to Their Safety for Dialysis Patients

    Article • Pharmaceutics, July 2022, MDPI AG

    MD-PhD GUY ROSTOKER

  17. Inflammation, Serum Iron, and Risk of Mortality and Cardiovascular Events in Nondialysis CKD Patients

    Article • Journal of the American Society of Nephrology, January 2022, American Society of Nephrology

    MD-PhD GUY ROSTOKER

  18. Why and how should we promote home dialysis for patients with end-stage kidney disease during and after the coronavirus 2019 disease pandemic? A French perspective

    Article • Journal of Nephrology, June 2021, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  19. A dialysis doctor’s memories with COVID-19 disease

    Article • Bulletin de la Dialyse à Domicile, May 2021, Registre de Dialyse Peritoneale de Langue Francaise (RDPLF)

    MD-PhD GUY ROSTOKER

  20. Analysis of liver iron concentration in an elderly female undergoing hemodialysis with calcific uremic arteriolopathy does not support the role of iron overload in calciphylaxis: lesson for the clinical nephrologist

    Article • Journal of Nephrology, January 2021, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  21. Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

    Article • Kidney International, December 2020, Elsevier

    MD-PhD GUY ROSTOKER

  22. Histological Scores Validate the Accuracy of Hepatic Iron Load Measured by Signal Intensity Ratio and R2* Relaxometry MRI in Dialysis Patients

    Article • Journal of Clinical Medicine, December 2019, MDPI AG

    MD-PhD GUY ROSTOKER

  23. Hepatic iron load differs strikingly between peritoneal dialysis and hemodialysis patients

    Article • Bulletin de la Dialyse à Domicile, December 2019

    MD-PhD GUY ROSTOKER

  24. What do we learn about the “Anemia Module” of the French language Peritoneal Dialysis ? Interest and Results

    Article • Bulletin de la Dialyse à Domicile, September 2019, Registre de Dialyse Peritoneale de Langue Francaise (RDPLF)

    MD-PhD GUY ROSTOKER

  25. Confounding factors of hazards of long-acting ESA

    Article • Journal of the American Society of Nephrology, August 2019, American Society of Nephrology

    MD-PhD GUY ROSTOKER

  26. Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations

    Article • Heliyon, July 2019, Elsevier

    MD-PhD GUY ROSTOKER

  27. Impact des comorbidités sur la stabilité de l’hémoglobine chez des patients insuffisants rénaux chroniques en hémodialyse, traités par CERA en pratique courante : l’étude MIRIADE

    Article • Néphrologie & Thérapeutique, June 2019, Elsevier

    MD-PhD GUY ROSTOKER

  28. Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study

    Article • EBioMedicine, January 2019, Elsevier

    MD-PhD GUY ROSTOKER

  29. La réalité de la dialyse péritonéale en France : 40 ans après

    Article • Néphrologie & Thérapeutique, December 2018, Elsevier

    MD-PhD GUY ROSTOKER

  30. When should iron supplementation in dialysis patients be avoided, minimized or withdrawn?

    Article • Seminars in Dialysis, June 2018, Wiley

    MD-PhD GUY ROSTOKER

  31. L’utilisation de génériques en transplantation : vers des solutions rationnelles et sures !

    Article • La Presse Médicale, March 2018, Elsevier

    MD-PhD GUY ROSTOKER

  32. Re: Further Evidence Supporting the Accuracy of Quantitative Magnetic Resonance Imaging for Evaluating Iron Load in Dialysis Patients

    Article • Kidney International Reports, January 2018, Elsevier

    MD-PhD GUY ROSTOKER

  33. Iatrogenic iron overload and its potential consequences in patients on hemodialysis

    Article • La Presse Médicale, December 2017, Elsevier

    MD-PhD GUY ROSTOKER

  34. The changing landscape of iron overload disorders at the beginning of the 21st century

    Article • La Presse Médicale, December 2017, Elsevier

    MD-PhD GUY ROSTOKER

  35. Hepatic Iron Load at Magnetic Resonance Imaging Is Normal in Most Patients Receiving Peritoneal Dialysis

    Article • Kidney International Reports, November 2017, Elsevier

    MD-PhD GUY ROSTOKER

  36. HFE gene mutations are not risk factors for iron overload in European hemodialysis patients

    Article • Hemodialysis International, March 2017, Wiley

    MD-PhD GUY ROSTOKER

  37. Impact of iatrogenic iron overload on the course of hepatitis C in the dialysis population: A plea for caution

    Article • Hemodialysis International, March 2017, Wiley

    MD-PhD GUY ROSTOKER

  38. Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study

    Article • BMC Nephrology, March 2017, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  39. Signal-intensity-ratio MRI accurately estimates hepatic iron load in hemodialysis patients

    Article • Heliyon, January 2017, Elsevier

    MD-PhD GUY ROSTOKER

  40. Intérêt de la dialyse péritonéale dans le traitement de l’insuffisance rénale aiguë de l’adulte : redécouverte d’une modalité complémentaire d’épuration extracorporelle continue

    Article • Néphrologie & Thérapeutique, July 2016, Elsevier

    MD-PhD GUY ROSTOKER

  41. Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century

    Article • Drugs, April 2016, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  42. Use of Iron Therapy in Chronic Kidney Disease

    Article • Archives of Clinical Nephrology, January 2016, Peertechz.com

    MD-PhD GUY ROSTOKER

  43. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

    Article • Kidney International, January 2016, Elsevier

    Professor Kamyar Kalantar-Zadeh, MD-PhD GUY ROSTOKER

  44. Utilisation des dérivés injectables du fer au cours de la maladie rénale chronique : intérêts, limites et conseils pour un bon usage

    Article • Néphrologie & Thérapeutique, December 2015, Elsevier

    MD-PhD GUY ROSTOKER

  45. Iatrogenic Iron Overload in Dialysis Patients

    Article • September 2015, IntechOpen

    MD-PhD GUY ROSTOKER

  46. Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study

    Article • PLOS One, July 2015, PLOS

    MD-PhD GUY ROSTOKER

  47. Maximal Standard Dose of Parenteral Iron for Hemodialysis Patients: An MRI-Based Decision Tree Learning Analysis

    Article • PLOS One, December 2014, PLOS

    MD-PhD GUY ROSTOKER

  48. Actualités sur la prise en charge de l’anémie et de la carence martiale du dialysé

    Article • Néphrologie & Thérapeutique, July 2014, Elsevier

    MD-PhD GUY ROSTOKER

  49. Magnetic Resonance Imaging Repercussions of Intravenous Iron Products Used for Iron-Deficiency Anemia and Dialysis-Associated Anemia

    Article • Journal of Computer Assisted Tomography, January 2014, Wolters Kluwer Health

    MD-PhD GUY ROSTOKER

  50. Traitement de l’addiction au tabac au cours des maladies rénales chroniques

    Article • Néphrologie & Thérapeutique, April 2013, Elsevier

    MD-PhD GUY ROSTOKER

  51. Hemodialysis

    Article • February 2013, IntechOpen

    MD-PhD GUY ROSTOKER

  52. Colloids in Dialytic Refractory Hypotension

    Article • February 2013, IntechOpen

    MD-PhD GUY ROSTOKER

  53. Single-Needle Hemodialysis on Native Fistulae

    Article • February 2013, IntechOpen

    MD-PhD GUY ROSTOKER

  54. Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI Study

    Article • The American Journal of Medicine, October 2012, Elsevier

    MD-PhD GUY ROSTOKER

  55. Modulation of oxidative stress and microinflammatory status by colloids in refractory dialytic hypotension

    Article • BMC Nephrology, October 2011, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  56. Cinacalcet to prevent parathyrotoxic crises in hypercalcaemic patients awaiting parathyroidectomy

    Article • BMJ Case Reports, May 2011, BMJ

    MD-PhD GUY ROSTOKER

  57. Renal Artery Stenosis Evaluation in Chronic Kidney Disease Patients: Nonenhanced Time-Spatial Labeling Inversion-Pulse Three-dimensional MR Angiography with Regulated Breathing versus DSA

    Article • Radiology, May 2011, Radiological Society of North America (RSNA)

    MD-PhD GUY ROSTOKER

  58. La technique d’hémodialyse transitoire en uniponcture sur fistules natives : intérêts, limites, risques et précautions

    Article • Néphrologie & Thérapeutique, December 2010, Elsevier

    MD-PhD GUY ROSTOKER

  59. Accuracy and limitations of equations for predicting the glomerular filtration rate during follow-up of patients with non-diabetic nephropathies

    Article • BMC Nephrology, June 2009, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  60. Left-Ventricular Diastolic Dysfunction as a Risk Factor for Dialytic Hypotension

    Article • Cardiology, January 2009, Karger Publishers

    MD-PhD GUY ROSTOKER

  61. Improving the Efficiency of Short-Term Single-Needle Hemodialysis

    Article • Renal Failure, January 2009, Taylor & Francis

    MD-PhD GUY ROSTOKER

  62. Secretory IgA are elevated in both saliva and serum of patients with various types of primary glomerulonephritis

    Article • Clinical & Experimental Immunology, June 2008, Wiley

    MD-PhD GUY ROSTOKER

  63. Quinze pour cent de patients dialysés traités par DPCA/DPA en 2010 : mythe ou réalité ?

    Article • Néphrologie & Thérapeutique, November 2006, Elsevier

    MD-PhD GUY ROSTOKER

  64. Candesartan Cilexetil on Regular Hemodialysis: Inability to Reduce Excessive Thirst, but Good Tolerance and Efficacy in Hypertensive Patients

    Article • Renal Failure, January 2006, Taylor & Francis

    MD-PhD GUY ROSTOKER

  65. Smoking cessation guidelines: evidence-based recommendations of the French Health Products Safety Agency

    Article • European Psychiatry, August 2005, Elsevier

    MD-PhD GUY ROSTOKER

  66. Les traitements médicamenteux du fibrome utérin

    Article • Journal de Gynécologie Obstétrique et Biologie de la Reproduction, June 2005, Elsevier

    MD-PhD GUY ROSTOKER

  67. Increased intestinal intra‐epithelial T lymphocytes in primary glomerulonephritis

    Article • Nephrology Dialysis Transplantation, March 2001, Oxford University Press (OUP)

    MD-PhD GUY ROSTOKER

  68. Sch??nlein-Henoch Purpura in Children and Adults

    Article • BioDrugs, January 2001, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  69. Vascular Hyperpermeability in Nephrotic Edema

    Article • January 2000, Karger Publishers

    MD-PhD GUY ROSTOKER

  70. Parvovirus B19 and Schönlein-Henoch Purpura in Adults

    Article • January 1999, Karger Publishers

    MD-PhD GUY ROSTOKER

  71. Imbalances in serum proinflammatory cytokines and their soluble receptors: a putative role in the progression of idiopathic IgA nephropathy (IgAN) and Henoch-Schonlein purpura nephritis, and a potential target of immunoglobulin therapy?

    Article • Clinical & Experimental Immunology, December 1998, Wiley

    MD-PhD GUY ROSTOKER

  72. Therapy of IgA Nephropathy

    Article • BioDrugs, January 1998, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  73. Recurrence of lecithin cholesterol acyltransferase deficiency after kidney transplantation

    Article • Nephrology Dialysis Transplantation, November 1997, Oxford University Press (OUP)

    MD-PhD GUY ROSTOKER

  74. Role of Lipoprotein-Bound NEFAs in Enhancing the Specific Activity of Plasma CETP in the Nephrotic Syndrome

    Article • Arteriosclerosis Thrombosis and Vascular Biology, November 1997, Wolters Kluwer Health

    MD-PhD GUY ROSTOKER

  75. Drug-induced linear IgA disease: target antigens are heterogeneous

    Article • British Journal of Dermatology, March 1997, Wiley

    MD-PhD GUY ROSTOKER

  76. A Cost Analysis of the Prevention of End-stage Renal Disease

    Article • Medical Decision Making, October 1996, SAGE Publications

    MD-PhD GUY ROSTOKER

  77. Therapy of Idiopathic Membranous Nephropathy

    Article • Clinical Immunotherapeutics, July 1996, Springer Science + Business Media

    MD-PhD GUY ROSTOKER

  78. Renal involvement in toxic epidermal necrolysis

    Article • Journal of the American Academy of Dermatology, June 1996, Elsevier

    MD-PhD GUY ROSTOKER

  79. Type I membranoproliferative glomerulonephritis and HCV infection

    Article • Nephrology Dialysis Transplantation, January 1996, Oxford University Press (OUP)

    MD-PhD GUY ROSTOKER

  80. Further identification of human plasma glycoproteins interacting with the galactose-specific lectin Jacalin

    Article • Journal of Chromatography B Biomedical Sciences and Applications, June 1995, Elsevier

    MD-PhD GUY ROSTOKER

  81. Immunomodulation with Low-Dose Immunoglobulins for Moderate IgA Nephropathy and Henoch-Schönlein Purpura

    Article • January 1995, Karger Publishers

    MD-PhD GUY ROSTOKER

  82. Low Prevalence of Antibodies to Hepatitis C Virus among Adult Patients with Idiopathic Membranoproliferative Type I Glomerulonephritis in France

    Article • January 1995, Karger Publishers

    MD-PhD GUY ROSTOKER

  83. Prevention of Thrombotic Complications of the Nephrotic Syndrome by the Low-Molecular-Weight Heparin Enoxaparin

    Article • January 1995, Karger Publishers

    MD-PhD GUY ROSTOKER

  84. Split tolerance in chimeric GVH mice

    Article • Transplant International, December 1994, Wiley

    MD-PhD GUY ROSTOKER

  85. High-Dose Immunoglobulin Therapy for Severe IgA Nephropathy and Henoch-Schonlein Purpura

    Article • Annals of Internal Medicine, March 1994, American College of Physicians

    MD-PhD GUY ROSTOKER

  86. Evaluation of Magnetic Resonance Imaging for the Assessment of Renal Vein Thrombosis in the Nephrotic Syndrome

    Article • January 1994, Karger Publishers

    MD-PhD GUY ROSTOKER

  87. Histone-Reactive IgA Antibodies in Adult IgA Nephropathy and Other Primary Glomerulonephritis

    Article • January 1994, Karger Publishers

    MD-PhD GUY ROSTOKER

  88. Long-Term Cyclosporin A Therapy for Severe Idiopathic Membranous Nephropathy

    Article • January 1993, Karger Publishers

    MD-PhD GUY ROSTOKER

  89. Mucosal Immunity in Primary Glomerulonephritis

    Article • January 1993, Karger Publishers

    MD-PhD GUY ROSTOKER

  90. Proteinuria Selectivity Index -Prognostic Value in Lipoid Nephrosis and Related Diseases

    Article • January 1993, Karger Publishers

    MD-PhD GUY ROSTOKER

  91. Intravenous IgG for glomerulonephritis and renal function

    Article • The Lancet, July 1991, Elsevier

    MD-PhD GUY ROSTOKER

  92. L'ischémie myocardique silencieuse au cours de l'hémodialyse des insuffisants rénaux chroniques

    Article • La Revue de Médecine Interne, March 1991, Elsevier

    MD-PhD GUY ROSTOKER

  93. Heparin Cofactor II in Adult Glomerulopathy and Nephrotic Syndrome

    Article • American Journal of Nephrology, January 1991, Karger Publishers

    MD-PhD GUY ROSTOKER

  94. Mucosal Immunity in Primary Glomerulonephritis: II. Study of the Serum IgA Subclass Repertoire to Food and Airborne Antigens

    Article • January 1991, Karger Publishers

    MD-PhD GUY ROSTOKER

  95. IgA mesangial nephritis, IgA antigliadin antibodies, and coeliac disease

    Article • The Lancet, September 1990, Elsevier

    MD-PhD GUY ROSTOKER

  96. Correspondence

    Article • American Journal of Kidney Diseases, August 1990, Elsevier

    MD-PhD GUY ROSTOKER

  97. HBV-DNA and Primary Immune Complex Glomerulonephritis

    Article • January 1990, Karger Publishers

    MD-PhD GUY ROSTOKER

  98. Mucosal Immunity in Adult Primary Glomerulonephritis

    Article • January 1990, Karger Publishers

    MD-PhD GUY ROSTOKER

  99. Reactivation of Hepatitis B Virus by Corticosteroids in a Case of Idiopathic Nephrotic Syndrome

    Article • January 1990, Karger Publishers

    MD-PhD GUY ROSTOKER

  100. CYCLOSPORIN IN IDIOPATHIC STEROID-RESISTANT MEMBRANOUS GLOMERULONEPHRITIS

    Article • The Lancet, October 1989, Elsevier

    MD-PhD GUY ROSTOKER

  101. IgA Antigliadin Antibodies as a Possible Marker for IgA Mesangial Glomerulonephritis in Adults with Primary Glomerulonephritis

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, May 1989, New England Journal of Medicine (NEJM/MMS)

    MD-PhD GUY ROSTOKER

  102. Idiopathic Nephrotic Syndrome: The Prognosis Is Not Linked to the Total Serum IgE Level

    Article • January 1989, Karger Publishers

    MD-PhD GUY ROSTOKER

  103. GANCICLOVIR FOR SEVERE CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS

    Article • The Lancet, November 1988, Elsevier

    MD-PhD GUY ROSTOKER

  104. IgA antigliadin antibodies detected by ELISA are not an artifact due to lectin-like activity of gliadin

    Article • Journal of Immunological Methods, August 1988, Elsevier

    MD-PhD GUY ROSTOKER

  105. HIGH LEVELS OF IgA ANTIGLIADIN ANTIBODIES IN PATIENTS WHO HAVE IgA MESANGIAL GLOMERULONEPHRITIS BUT NOT COELIAC DISEASE

    Article • The Lancet, February 1988, Elsevier

    MD-PhD GUY ROSTOKER

  106. Total and free protein S in nephrotic syndrome

    Article • Thrombosis Research, January 1988, Elsevier

    MD-PhD GUY ROSTOKER

  107. Lack of Antireticulin and IgA Antiendomysium Antibodies in Sera of Patients with Primary IgA Nephropathy Associated with Circulating IgA Antibodies to Gliadin

    Article • January 1988, Karger Publishers

    MD-PhD GUY ROSTOKER

  108. FOOD ALLERGY IN IDIOPATHIC NEPHROTIC SYNDROME

    Article • The Lancet, August 1987, Elsevier

    MD-PhD GUY ROSTOKER

  109. Cutaneous granuloma over a vitallium plate

    Article • Contact Dermatitis, March 1987, Wiley

    MD-PhD GUY ROSTOKER

  110. An Increase in Circulating IgA Antibodies to Gliadin in IgA Mesangial Glomerulonephritis

    Article • American Journal of Nephrology, January 1987, Karger Publishers

    MD-PhD GUY ROSTOKER

  111. High Level of Protein C and Protein S in Nephrotic Syndrome

    Article • January 1987, Karger Publishers

    MD-PhD GUY ROSTOKER

  112. Is Adult Idiopathic Nephrotic Syndrome Food Allergy?

    Article • January 1987, Karger Publishers

    MD-PhD GUY ROSTOKER

  113. Coexistence of Sézary syndrome and dysmyelopoiesis with an excess of myeloblasts

    Article • Journal of the American Academy of Dermatology, December 1986, Elsevier

    MD-PhD GUY ROSTOKER